Current international guidelines for the management of community acquired pneumonia
(CAP) recommend therapy with a β-lactam plus a macrolide or a 'respiratory'fluoroquinolone …

Scope To study the factors associated with mortality in hospitalized patients with community‐
acquired pneumonia treated with monotherapy or combination therapy. Methods PubMed …

Guidelines for inpatients with community-acquired pneumonia (CAP) propose to use
respiratory fluoroquinolone (RFQ) and/or third-generation cephalosporins (Ceph-3) …

Importance Antibiotic therapy is the cornerstone of medical management for community-
acquired pneumonia. Objective To assess the associations between 3 key aspects of …

Community-acquired pneumonia (CAP) is a common but potentially life-threatening
condition, but limited information exists on the effectiveness of fluoroquinolones compared to …

Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the
management of community‐acquired pneumonia (CAP). Methods: Data were collected from …

Adding either macrolide or fluoroquinolone (FQ) to β-lactam has been recommended for
patients with severe community-acquired pneumonia (CAP). However, due to the limited …

Background The choice of empirical antibiotic treatment for patients with clinically suspected
community-acquired pneumonia (CAP) who are admitted to non–intensive care unit (ICU) …

OBJECTIVE: In this observational study, we compared the outcomes of moxifloxacin
monotherapy as compared to ß-lactam monotherapy as well as ß-lactam combination …

Based on recent guidelines for the management of community-acquired pneumonia, this
study was designed to evaluate the effectiveness of a new fluoroquinolone compared with …